证券代码：688136 证券简称：科兴制药 公告编号：2023-052 科兴生物制药股份有限公司 2023 年半年度募集资金存放及实际使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 | 项目 | 募集资金使用情况 | | --- | --- | | 募集资金总额 | 1,109,249,449.00 | | 减：发行费用 | 114,608,529.84 | | 募集资金净额 | 994,640,919.16 | | 减：募投项目累计投入金额 | 707,411,529.46 | 第 1 页 根据《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要 求》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》和《上 海证券交易所科创板股票上市规则》等有关规定，科兴生物制药股份有限公司（以 下简称"本公司"或"公司"）董事会对 2023 年半年度募集资金存放和实际使 用情况专项报告说明如下： 一、募集资金基本情况 经中国证券监督管理委员会出具的《关于同意科兴生物制药股份有限公司首 ...

科兴生物制药股份有限公司 第二届董事会第九次会议 科兴生物制药股份有限公司独立董事 关于第二届董事会第九次会议相关议案的 独立意见 根据《中华人民共和国公司法》《上海证券交易所科创板股票上市规则》《上 市公司治理准则》等要求以及《科兴生物制药股份有限公司章程》（以下简称"《公 司章程》"）的相关规定，作为科兴生物制药股份有限公司（以下简称"公司"） 第二届董事会独立董事，我们参加了公司第二届董事会第九次会议，在认真审阅 并全面了解公司提供的相关资料的基础上，现就第二届董事会第九次会议相关议 案发表如下独立意见： 一、关于公司 2023 年半年度募集资金存放及实际使用情况的专项报告的独 立意见 我们认为：公司 2023 年半年度募集资金存放及使用情况符合《上市公司监 管指引第 2 号——上市公司募集资金管理和使用的监管要求》《上海证券交易所 科创板上市公司自律监管指引第 1 号——规范运作》以及公司《募集资金管理制 度》等法律法规、规范性文件和公司制度的规定，对募集资金进行了专户存储和 专项使用，并及时履行了相关信息披露义务，募集资金具体使用情况与公司已披 露情况一致，不存在变相改变募集资金用途和损害股东利益的 ...

一、监事会会议召开情况 科兴生物制药股份有限公司（以下简称"公司"）第二届监事会第九次会议 于 2023 年 8 月 24 日以现场表决方式召开。会议通知已于 2023 年 8 月 21 日发 出。本次会议应出席监事 3 人，实际出席监事 3 人。 会议由监事会主席江海燕主持。会议召开符合有关法律、法规、规章和《公 司章程》的规定。 证券代码：688136 证券简称：科兴制药 公告编号：2023-051 科兴生物制药股份有限公司 第二届监事会第九次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 具体内容详见公司同日披露于上海证券交易所网站（www.sse.com.cn）的《公 司 2023 年半年度报告》及《公司 2023 年半年度报告摘要》。 （二）审议通过《关于公司 2023 年半年度募集资金存放及实际使用情况的 专项报告的议案》 公司监事会认为：公司 2023 年半年度募集资金存放及使用情况符合《上市 公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求》《上海证券 交易所科创板上市公司自律监 ...

重要内容提示： 会议召开时间：2023 年 09 月 01 日(星期五) 下午 14:00-15:00 证券代码：688136 证券简称：科兴制药 公告编号：2023-050 科兴生物制药股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 会议召开地点：上海证券交易所上证路演中心（网址： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 08 月 25 日(星期五)至 08 月 31 日(星期 四)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通 过公司邮箱 ir@kexing.com 进行提问。公司将在说明会上对投资者普 遍关注的问题进行回答。 科兴生物制药股份有限公司（以下简称"公司"）将于 2023 年 8 月 26 日发布公司 2023 年半年度报告，为便于广大投资者更全面深入 地了解公司 2023 年半年度经营成果、财务状况，公司计划于 2023 年 09 月 01 日下午 ...

北京市嘉源律师事务所 关于科兴生物制药股份有限公司 2023 年第二次临时股东大会的 法律意见书 西城区复兴门内大街 158 号远洋大厦 4 楼 中国·北京 EUM E 3 FT YUAN LAW OFFICES 北京市嘉源律师事务所 关于科兴生物制药股份有限公司 2023 年第二次临时股东大会的 法律意见书 嘉源(2023) -04-619 北京市嘉源律师事务所(以下简称"本所")接受科兴生物制药股份有限公 司(以下简称"公司")的委托,根据《中华人民共和国公司法》(以下简称"《公 司法》"）《上市公司股东大会规则》〈以下简称"《股东大会规则》"）等现 行有效的法律、行政法规、部门规章、规范性文件(以下简称"法律法规")以 及《科兴生物制药股份有限公司章程》(以下简称"《公司章程》")的有关规 定,指派本所律师对公司2023年第二次临时股东大会(以下简称"本次股东大会") 进行见证,并依法出具本法律意见书。 为出具本法律意见书,本所指派律师现场见证了本次股东大会,查阅了公司 提供的与本次股东大会有关的文件和资料,并进行了必要的审查和验证。在前达 审查和验证的过程中,本所律师得到公司的如下承诺和保证:就本所认 ...

证券代码：688136 证券简称：科兴制药 公告编号：2023-049 科兴生物制药股份有限公司 2023 年第二次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2023 年 8 月 10 日 （二） 股东大会召开的地点：深圳市南山区高新中一道与科技中一路交汇处创 益科技大厦 B 栋 19 楼会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 16 | | --- | --- | | 普通股股东人数 | 16 | | 2、出席会议的股东所持有的表决权数量 | 135,984,740 | | 普通股股东所持有表决权数量 | 135,984,740 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比例 | 68.2659 | | （%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） ...

Financial Performance - The company's operating revenue for 2022 was approximately ¥1.316 billion, representing a 2.39% increase compared to ¥1.285 billion in 2021[24]. - The net profit attributable to shareholders of the listed company for 2022 was a loss of approximately ¥90.295 million, a decrease of 193.61% from a profit of ¥96.464 million in 2021[24]. - The basic earnings per share for 2022 was -¥0.45, a decline of 191.84% compared to ¥0.49 in 2021[25]. - The net cash flow from operating activities for 2022 was -¥85.888 million, a decrease of 191.36% from ¥94.013 million in 2021[24]. - The total assets at the end of 2022 were approximately ¥3.159 billion, an increase of 11.65% from ¥2.829 billion at the end of 2021[24]. - The weighted average return on net assets for 2022 was -4.87%, down from 5.16% in 2021[25]. - The company reported a significant decrease in fair value gains, with a loss of -¥5,350,509.21 compared to a gain of ¥47,458,024.75 in the previous year, reflecting a 111.27% decline[122]. - The company achieved total operating revenue of CNY 1,315.88 million in 2022, a year-on-year increase of 2.39%[34]. - The net profit attributable to the parent company was CNY -90.30 million, a year-on-year decrease of 193.61%[34]. Research and Development - In 2022, the company's R&D expenses increased by 57.21% year-on-year, amounting to 70.35 million RMB[4]. - Research and development expenses increased by 57.21% year-on-year, accounting for 14.69% of operating revenue in 2022[25]. - The company is actively expanding its R&D team, with a notable increase in high-level R&D personnel compared to the previous year[4]. - The company has introduced several senior pharmaceutical PhDs with extensive experience from multinational pharmaceutical companies, enhancing the R&D team's capabilities[40]. - The company applied for 17 new invention patents and obtained 5 new invention patents in 2022, totaling 45 patents by the end of the year[38]. - The company has established a joint innovation laboratory with Shenzhen University to explore probiotic research and has submitted 4 invention patent applications[39]. - The company is focusing on expanding its product pipeline in the fields of antiviral, oncology, and immunology, optimizing R&D processes[36]. - The company has multiple R&D projects that have entered clinical stages, indicating a robust pipeline for future product development[75]. - The company has received 5 clinical trial approval notices, including projects for recombinant human interferon α2b spray and capsule, and Shen26 capsule project[79]. - The company achieved a research and development investment of 193.30 million RMB, representing a year-on-year increase of over 57.21%[141]. Market Expansion and Sales - The company has made significant progress in overseas commercialization and has seen rapid growth in export revenue[34]. - In 2022, the company achieved overseas sales revenue of $161 million, a 61% increase year-over-year, marking a historical high[41]. - The company has submitted product registration applications to over 30 countries, with expectations for some products to be launched in 2023[42]. - The company has established subsidiaries in Singapore, Mexico, Egypt, and Brazil to enhance its international market competitiveness[41]. - The market share of "Sairuo Jin®" in the domestic short-acting interferon market reached 35.65%, maintaining the top position for several years[46]. - The company has signed partnerships for five products, expanding its product pipeline in oncology and immunology[42]. - The company has a complete and controllable R&D, procurement, production, and marketing system, focusing on recombinant protein drugs and new technologies such as antibody drugs and gene engineering vaccines[60]. - The company has established a marketing distribution network covering nearly 20,000 various terminal points in the domestic market, primarily using a distribution-based sales model[61]. - The company is set to enter mass production of α-ketoglutarate and 5-aminolevulinic acid in 2023, enhancing its competitive edge in synthetic biology[52]. - The company is expanding its market presence in Southeast Asia, targeting a 30% increase in sales in that region[174]. Financial Risks and Challenges - The company faces risks related to maintaining substantial R&D investments and high interest expenses, which could lead to continued losses if adverse changes occur in the macroeconomic environment or industry competition[4]. - The company has reported a significant increase in financial expenses, rising by 196.88% year-on-year, totaling 14.92 million RMB[4]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[9]. - The company has received a standard unqualified audit report from Da Hua Accounting Firm[6]. - The company faces risks related to supply chain disruptions from overseas suppliers, which could impact operations due to global economic uncertainties[95]. Corporate Governance and Management - The company has not disclosed any special arrangements for corporate governance or significant matters[10]. - The company has a stable management team with no significant changes in personnel during the reporting period[172]. - The company continues to focus on maintaining independence from its controlling shareholder in business operations[166]. - The company has established a performance evaluation system for directors and senior management based on industry standards and individual performance[184]. - The company has implemented a stock incentive plan for 2022, aimed at motivating key personnel[193]. Future Outlook - Future outlook indicates a projected revenue growth of 15% year-over-year, driven by new product launches and market expansion strategies[173]. - The company provided guidance for the next fiscal year, projecting revenue growth of 25% to $625 million[174]. - The company plans to enhance its digital marketing efforts, allocating 61.55 million for this initiative in the next fiscal year[173]. - The company is considering strategic acquisitions to enhance its product portfolio and market presence[173]. - A new product line is expected to launch in Q2 2023, anticipated to contribute an additional 10% to overall revenue[173].

Financial Performance - The net profit attributable to the parent company showed a significant decline, resulting in a loss compared to the same period last year[4]. - The company's operating revenue for 2022 was approximately RMB 1.316 billion, representing a 2.39% increase compared to RMB 1.285 billion in 2021[24]. - The net profit attributable to shareholders of the listed company for 2022 was a loss of approximately RMB 90.295 million, a decrease of 193.61% from a profit of RMB 96.464 million in 2021[24]. - The basic earnings per share for 2022 was -0.45 yuan, down 191.84% from 0.49 yuan in 2021[25]. - The total assets of the company at the end of 2022 were approximately RMB 3.159 billion, an increase of 11.65% from RMB 2.829 billion at the end of 2021[24]. - The net cash flow from operating activities for 2022 was a negative RMB 85.888 million, a decline of 191.36% compared to RMB 94.013 million in 2021[24]. - The company reported a significant decline in fair value gains, with a loss of CNY -5,350,509.21 compared to a gain of CNY 47,458,024.75 in the previous year, indicating market volatility[118]. - The company achieved total revenue of 1,315,875,590.34 CNY, representing a year-on-year growth of 2.39%[99]. - The company reported a significant increase in revenue, achieving a total of $500 million for the fiscal year, representing a 20% growth year-over-year[171]. Research and Development - In 2022, the company's R&D expenses increased by 57.21% year-on-year, amounting to 70.35 million RMB[4]. - The company is actively expanding its R&D team, with a significant increase in high-level R&D personnel compared to the previous year[4]. - Research and development expenses increased by 57.21% year-on-year, accounting for 14.69% of operating revenue in 2022[25]. - The company has introduced several senior pharmaceutical PhDs with extensive experience from multinational pharmaceutical companies to enhance its R&D capabilities[40]. - The company is focusing on expanding its product pipeline in the fields of antiviral, oncology, and immune diseases[36]. - The company has made significant advancements in inhalation formulation technology, achieving domestic leadership in this area[69][70]. - The company has seen a 20% increase in R&D personnel with master's degrees or higher during the reporting period[75]. - The company is actively pursuing clinical trials for multiple R&D projects, indicating a robust pipeline for future product development[75]. - The company has received five clinical trial approval notices for various projects, including the polyethylene glycol recombinant human granulocyte colony-stimulating factor injection project[134]. - The company achieved a research and development investment of 193.30 million RMB, representing a year-on-year increase of over 57.21%[138]. Market Expansion and Sales - The company has made significant progress in overseas commercialization and has seen rapid growth in export revenue[34]. - In 2022, the company achieved overseas sales revenue of $161 million, a 61% increase year-over-year, marking a historical high[41]. - The company has established subsidiaries in Singapore, Mexico, Egypt, and Brazil to enhance its international market competitiveness[41]. - The company has established a marketing distribution network covering nearly 20,000 terminals in the domestic market[61]. - The company is focusing on international business expansion and deepening its presence in emerging markets, while domestic market revenue has shown a slight decline[102]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share within the next two years[171]. - The company is considering strategic acquisitions to enhance its market position, targeting firms with a combined revenue of 500 million[178]. Corporate Governance - The company has not proposed any special arrangements for corporate governance in the report[10]. - The company emphasizes that forward-looking statements regarding future plans and strategies do not constitute substantive commitments to investors[8]. - There were no significant differences in corporate governance compared to regulations set by the China Securities Regulatory Commission[164]. - The company maintained a consistent governance structure without any significant changes in voting rights or red-chip architecture during the reporting period[167]. - The total remuneration for the chairman was reported at 0 million yuan, while the general manager received 106.63 million yuan[169]. - The company has a clear strategy for maintaining independence from its controlling shareholder, ensuring autonomous operational capabilities[164]. Risks and Challenges - The company faces potential risks of continued losses if it maintains substantial R&D investments or if there are adverse changes in the macroeconomic environment, industry policies, competitive landscape, or downstream demand[4]. - The company has detailed potential risks in the "Management Discussion and Analysis" section of the report[4]. - The company faces risks related to reliance on overseas suppliers for key raw materials, which may impact operations due to potential supply delays or price increases[94]. - The company emphasizes strict quality management in compliance with national regulations to mitigate risks associated with drug quality control[94]. Employee and Management Structure - The total number of employees in the parent company is 597, while the main subsidiaries employ 810, resulting in a total of 1,407 employees[194]. - The company has 208 R&D personnel, indicating a strong focus on research and development[194]. - The management team consists of experienced professionals with diverse backgrounds in finance and operations, enhancing strategic decision-making[170]. - The company has a competitive salary structure that includes basic salary, performance pay, performance bonuses, and position allowances[195]. - The company emphasizes a diversified incentive system to enhance employee engagement and performance[196]. Future Outlook - The company provided guidance for the next fiscal year, projecting revenue growth of 25% to $625 million[171]. - Future guidance indicates a focus on technological advancements and new product development to drive growth[170]. - The overall outlook remains positive, with expectations for continued growth and market expansion initiatives[170]. - The company plans to deepen cooperation with leading enterprises in the animal health industry to enhance its product pipeline and commercialization[154].

Financial Performance - The company's operating revenue for Q1 2023 was ¥322,637,429.95, representing a year-on-year increase of 19.62%[5] - The net profit attributable to shareholders was a loss of ¥8,766,132.94, reflecting a decrease of 130.11% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of ¥12,471,455.76, down 144.79% year-on-year[5] - The net cash flow from operating activities was a negative ¥46,596,985.36, a decline of 343.13% compared to the previous year[5] - Operating profit for Q1 2023 was -¥17,131,632.71, a decline from a profit of ¥30,436,415.62 in Q1 2022[20] - The company reported a net loss of ¥17,307,133.56 for Q1 2023, compared to a net profit of ¥30,315,051.61 in Q1 2022[20] - In Q1 2023, the company reported a net loss of CNY 9,859,490.11, compared to a net profit of CNY 29,109,430.39 in Q1 2022, indicating a significant decline in profitability[21] - The company's basic and diluted earnings per share for Q1 2023 were both CNY -0.04, down from CNY 0.38 in the same period last year[21] Research and Development - Research and development expenses totaled ¥48,607,343.41, an increase of 63.45% year-on-year, accounting for 15.07% of operating revenue, up 4.04 percentage points[6] - Research and development expenses increased to ¥48,607,343.41 in Q1 2023, compared to ¥29,737,687.82 in Q1 2022, reflecting a growth of 63.4%[20] - The company plans to continue investing in R&D to enhance product offerings and market competitiveness[20] - The company is actively advancing the Phase I clinical trial of human interferon α1b inhalation solution, with the first subject enrolled in January 2023[14] - The State Drug Administration accepted the clinical trial application for "human growth hormone injection" in April 2022, indicating progress in product development[14] Assets and Liabilities - The total assets at the end of the reporting period were ¥3,117,663,584.05, a decrease of 1.30% from the end of the previous year[6] - The total assets as of Q1 2023 amounted to ¥3,117,663,584.05, a decrease from ¥3,158,711,687.22 at the end of the previous period[17] - Total liabilities for Q1 2023 were ¥1,319,301,301.44, down from ¥1,352,870,907.21 in the previous period[17] - The company's equity attributable to shareholders was ¥1,801,984,263.00, slightly down from ¥1,808,369,403.23 in the previous period[17] Cash Flow - Cash and cash equivalents decreased to ¥126,385,765.00 from ¥162,693,510.00, indicating a reduction of 22.3%[17] - The company's cash and cash equivalents were reported at ¥483,679,482.09, down from ¥785,382,355.26, indicating a significant decrease of about 38.4%[15] - Cash and cash equivalents at the end of Q1 2023 totaled CNY 482,267,798.61, down from CNY 885,852,798.64 at the end of Q1 2022[23] - The company experienced a net decrease in cash and cash equivalents of CNY -301,702,977.66 in Q1 2023, contrasting with a net increase of CNY 11,075,926.74 in Q1 2022[23] - Operating cash inflow for Q1 2023 was CNY 322,682,139.39, a slight increase from CNY 302,960,530.43 in Q1 2022[22] - The net cash flow from operating activities was CNY -46,596,985.36, worsening from CNY -10,515,309.38 in Q1 2022[22] - Investment activities resulted in a net cash outflow of CNY -296,153,447.14, compared to CNY -127,319,389.61 in the previous year[23] - The company received CNY 360,000,000.00 from investment recoveries in Q1 2023, significantly higher than CNY 160,000,000.00 in Q1 2022[23] - Total cash inflow from financing activities was CNY 158,810,321.95, compared to CNY 198,816,633.02 in Q1 2022[23] - The company reported a cash outflow of CNY 101,989,908.60 for debt repayment in Q1 2023, up from CNY 39,500,000.00 in the same period last year[23] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 10,868[10] - The top shareholder, Qingdao Hengyi Enterprise Management Partnership, holds 2,440,999 shares, representing a significant portion of the company's equity[13] - The total number of shares held by the top ten shareholders includes significant stakes from natural persons such as Nie Rulong and Zhu Nengshun, with holdings of 1,888,888 and 1,740,217 shares respectively[13]

会议召开方式：上证路演中心视频直播和网络互动 投资者可于 2023 年 04 月 21 日(星期五) 至 04 月 27 日(星期四)16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或或通过公司邮箱 ir@kexing.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 科兴生物制药股份有限公司（以下简称"公司"）已于 2023 年 4 月 22 日发 布公司 2022 年度报告，为便于广大投资者更全面深入地了解公司 2022 年度经营 成果、财务状况，公司计划于 2023 年 04 月 28 日下午 15:00-16:30 举行 2022 年 度业绩说明会，就投资者关心的问题进行交流。 证券代码：688136 证券简称：科兴制药 公告编号：2023-022 科兴生物制药股份有限公司 关于召开 2022 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 会议召开时间：2023 年 04 月 28 日(星期五) 下午 15:00-16:30 会议召开地点： ...